Estudo de avaliação da custo-efetividade de brodalumabe dentre os medicamentos imunobiológicos disponíveis para o tratamento da psoríase em placas moderada a grave em adultos no Sistema de Saúde Suplementar no Brasil

Paulo Antônio Oldani Felix; Marcos Santos; Aline Maria Fortuna Magalhães; Lucas Giglio Colli; Daniel Henrique Oliveira Fonseca; Giovana de Santana Gouveia; Guilherme Muzy

doi:10.66305/jbas.v5i1.32

Cost-Effectiveness of Brodalumab Compared with Available Biologic Therapies for Moderate-to-Severe Plaque Psoriasis in Adults in the Brazilian Supplementary Health System

Authors

Paulo Antônio Oldani Felix Serviço de Dermatologia, Hospital Federal dos Servidores do Estado, Rio de Janeiro, RJ, Brasil
Marcos Santos Departamento de Rádio-Oncologia, Grupo CONFIAR, Goiânia, GO, Brasil
Aline Maria Fortuna Magalhães LEO Pharma Ltda, São Paulo, SP, Brasil
Lucas Giglio Colli LEO Pharma Ltda, São Paulo, SP, Brasil
Daniel Henrique Oliveira Fonseca LEO Pharma Ltda, São Paulo, SP, Brasil
Giovana de Santana Gouveia LEO Pharma Ltda, São Paulo, SP, Brasil
Guilherme Muzy Clínica Muzy, São Paulo, SP, Brasil

DOI:

https://doi.org/10.66305/jbas.v5i1.32

Keywords:

Cost-Effectiveness, Brodalumab, Psoriasis

Abstract

The study evaluates the cost-effectiveness of brodalumab compared with other biologic therapies available for the treatment of moderate-to-severe plaque psoriasis in adults in the Brazilian supplementary health system.

Downloads

PDF (Português (Brasil))

Published

2025-05-30

How to Cite

Antônio Oldani Felix, P., Santos, M., Maria Fortuna Magalhães, A., Giglio Colli, L., Henrique Oliveira Fonseca, D., de Santana Gouveia, G., & Muzy, G. (2025). Cost-Effectiveness of Brodalumab Compared with Available Biologic Therapies for Moderate-to-Severe Plaque Psoriasis in Adults in the Brazilian Supplementary Health System. Brazilian Journal of Health Auditing, 5(1), 3–15. https://doi.org/10.66305/jbas.v5i1.32